Abstract

p38a is a significant target for drug designing against cancer. The overproduction of p38a MAPK promotes tumorigenesis inhead and neck squamous cell carcinoma (HNSCC). The ATP binding and an allosteric site referred as DFG are the key sites ofthe p38a mitogen activated protein kinase (MAPK) exploited for the design of inhibitors. The p38 mitogen-activated protein kinase (MAPK) is a signaling intermediate downstream of proinflammatory cytokine receptors released following environmental stress. This kinase is known to play an important role in inflammatory and autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. Here, we present for the first time a novel drug-target combined Bayesian formulation for the Rational Discovery of a Specific FWCS/LQIHFTLIXAFCCEN Peptide mimetic Pharmacophoric Inhibitor against p38a MAPK at Allosteric-Sites-HNSCC. A Therapeutic Modality forHNSCC using Predicting drug–target interactions from chemical and genomic kernels by Bayesian matrix factorization. This paper discusses quantum mechanical schemas for describing waves with non-abelian phases, Fock spaces of annihilation-creation operators for these structures, and the Feynman recipe for obtaining descriptions of particle interactions with external novel drug-target fields combined to Bayesian formulation for the Rational Discovery of a Specific FWCS/LQIHFTLIXAFCCEN Peptide mimetic Pharmacophoric Inhibitor against p38a MAPK at HNSCC Allosteric-Sites on Hypercomplex based Extensions of Quantum Theory.

Keywords

novel; drug-target;combined; Bayesian formulation;Rational Discovery; FWCS/LQIHFTLIXAFCCEN;Peptide mimetic;Pharmacophoric Inhibitor;p38a MAPK; Allosteric-Sites;HNSCC; A novel drug-target combined Bayesian formulation for the Rational Discovery of a Specific; Hypercomplex Extensions; Quantum Theory; novel drug-target; Bayesian formulation; Allosteric-Sites; Composition Algebras; Hilbert Spaces; Fock Spaces; Non-Abelian Gauge Fields;